Subgroup analyses further revealed that this beneficial effect was consistent across various subgroups—regardless of the delirium assessment tool (CAM-ICU or others), anesthesia type (general or non-general), surgery type (cardiac or non-cardiac), patient age (< 65 or ≥65 years), or insulin dosage (20 IU or 40 IU). This evidence concerns the gene INS and delirium.